Gossamer bio to present at upcoming investor conferences

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced that the company will present at the following investor conferences in september. cantor global healthcare conference   date / time: september 3rd, at 9:10 am et format:.
GOSS Ratings Summary
GOSS Quant Ranking